Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
(Thomson Reuters ONE) -
REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
(Nasdaq:CHRS) announced today the pricing of its initial public offering of
6,296,300 shares of its common stock at a public offering price of $13.50 per
share, before underwriting discounts, commissions and estimated expenses. All of
the shares of common stock are being offered by Coherus. The Company's common
stock has been approved for listing on the NASDAQ Global Market and is expected
to begin trading today under the ticker symbol "CHRS". In addition, Coherus has
granted the underwriters a 30-day option to purchase up to 944,445 additional
shares of common stock at the offering price. The offering is expected to close
on November 12, 2014, subject to customary closing conditions.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as
joint book-running managers and Cowen and Company, LLC is acting as lead manager
for the offering.
A registration statement relating to these securities was declared effective by
the Securities and Exchange Commission on November 6, 2014. The offering is
being made only by means of a prospectus, copies of which may be obtained by
contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or Credit Suisse,
Attention: Prospectus Department, One Madison Avenue, New York, NY 10010.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state or other jurisdiction.
About Coherus BioSciences, Inc.
Coherus is a late-stage biologics platform company focused on the global
biosimilar market. Headquartered in the San Francisco Bay Area and composed of a
team of industry veterans with decades of experience in pioneering biologics
companies, our goal is to become a global leader in the biosimilar market by
leveraging our team's collective expertise in key areas such as process science,
analytical characterization, protein production and clinical-regulatory
development. Our commercialization partnerships include global pharmaceutical
companies in Europe, Asia and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to
treat a range of chronic and often life-threatening diseases, with the potential
to reduce costs and expand patient access.
Contact Info:
Jean-Frédéric Viret, Ph.D.
Chief Financial Officer
Coherus BioSciences, Inc.
jviret(at)coherus.com
1 (800) 794-5434
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Coherus BioSciences via GlobeNewswire
[HUG#1869563]
Datum: 06.11.2014 - 18:13 Uhr
Sprache: Deutsch
News-ID 350513
Anzahl Zeichen: 3729
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock"
steht unter der journalistisch-redaktionellen Verantwortung von
Coherus BioSciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
